Free tool
FAERS Monitor: Piasky
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761388 or its brand name (Piasky, Crovalimab-Akkz). Reports on generic versions are filed under their own applications.
Reports
121
Serious
115
95% of reports
Hospitalization
69
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia21
- type iii immune complex mediated reaction21
- anaemia20
- off label use15
- haemolysis14
- infection11
- breakthrough haemolysis10
- pneumonia10
- hepatic function abnormal8
- covid-197
- haemoglobin decreased7
- sepsis7
- urinary tract infection7
- arthralgia6
- drug ineffective6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 12 |
| 2025 | 54 |
| 2026 | 55 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,038 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| type iii immune complex mediated reactionSignal | 21 | 6791.8 | 4562.3 | 130,775 |
| breakthrough haemolysisSignal | 10 | 4473.0 | 2450.2 | 39,339 |
| haemolysisSignal | 14 | 315.7 | 192.8 | 4,077 |
| hepatic function abnormalSignal | 8 | 37.3 | 19.1 | 248 |
| anaemiaSignal | 20 | 18.2 | 12.2 | 311 |
| infectionSignal | 11 | 13.2 | 7.5 | 113 |
| haemoglobin decreasedSignal | 7 | 11.9 | 5.8 | 59 |
| sepsisSignal | 7 | 10.9 | 5.3 | 54 |
| pyrexiaSignal | 21 | 10.6 | 7.2 | 175 |
| urinary tract infectionSignal | 7 | 7.1 | 3.5 | 31 |
| covid-19Signal | 7 | 6.9 | 3.4 | 30 |
| pneumoniaSignal | 10 | 5.4 | 3.0 | 32 |
| off label useSignal | 15 | 3.0 | 1.9 | 19 |
| arthralgiaSignal | 6 | 2.5 | 1.1 | 4 |
| drug ineffective | 6 | 0.8 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.